Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of the RB loss-induced transcriptome and E2F1 cistrome in prostate cancer

ABSTRACT: Identification of the RB loss-induced transcriptome and E2F1 cistrome in prostate cancer

PROVIDER: PRJNA374914 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5252910.fastq.gz	Fastqsanger.gz
	SRR5252911.fastq.gz	Fastqsanger.gz
	SRR5252906.fastq.gz	Fastqsanger.gz
	SRR5252907.fastq.gz	Fastqsanger.gz
	SRR5252908.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Comparison of the RB loss-induced E2F1 cistrome in hormone-therapy sensitive and castration-resistant prostate cancer [ChIP-seq]

Project description:These studies examine the consequence of RB loss on E2F1 function across prostate cancer progression.

2021-04-26 | GSE154191 | GEO

Identification of the RB loss-induced E2F1 cistrome in prostate cancer [ChIP-seq]

Project description:The retinoblastoma protein (RB) is preferentially lost in the progression to castrate resistant prostate cancer (CRPC). However, the alterations associated with such loss have been scantly described. The current study aims to provide molecular mechanisms underlying Rb loss-driven CRPC phenotypes.

2018-02-22 | GSE94958 | GEO

Comparison of the RB loss-induced E2F1 cistrome in hormone-therapy sensitive and castration-resistant prostate cancer [ChIP-seq]

Project description:Comparison of the RB loss-induced E2F1 cistrome in hormone-therapy sensitive and castration-resistant prostate cancer [ChIP-seq]

| PRJNA645395 | ENA

Identification of the impact of RB status on chromatin accessibility [ATAC-seq]

Project description:The retinoblastoma protein (RB) is preferentially lost in the progression to castrate resistant prostate cancer (CRPC). However, the alterations associated with such loss have been scantly described. Current findings have identified a novel E2F1 associated cistrome and transcriptome that is associated with RB loss in PCa. In order to determine the contribution of chromatin accessibility to alterations in E2F1 activity, ATAC-Seq was performed.

2018-02-22 | GSE105116 | GEO

E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis

Project description:The specific ablation of Rb1 gene in epidermis (RbF/F;K14cre) promotes proliferation and altered differentiation but does not produce spontaneous tumour development. These phenotypic changes are associated with increased expression of E2F members and E2F-dependent transcriptional activity. Here, we have focused on the possible dependence on E2F1 gene function. We have generated mice that lack Rb1 in epidermis in an inducible manner (RbF/F;K14creERTM). These mice are indistinguishable from those lacking pRb in this tissue in a constitutive manner (RbF/F;K14cre). In an E2F1-null background (RbF/F;K14creERTM; E2F1-/- mice), the phenotype due to acute Rb1 loss is not ameliorated by E2F1 loss, but rather exacerbated, indicating that pRb functions in epidermis do not rely solely on E2F1. On the other hand, RbF/F;K14creERTM;E2F1-/- mice develope spontaneous epidermal tumours of hair follicle origin with high incidence. These tumours, which retain a functional p19arf/p53 axis, also show aberrant activation of βcatenin/Wnt pathway. Gene expression studies revealed that these tumours display relevant similarities with specific human tumours. These data demonstrate that the Rb/E2F1 axis exerts essential functions not only in maintaining epidermal homeostasis, but also in suppressing tumour development in epidermis, and that the disruption of this pathway may induce tumour progression through specific alteration of developmental programs. Gene expression was compared between normal mouse skin, skin from transgenic RbF/F;K14creERTM; E2F1-/- , E2F1-/-, and RbF/F;K14creERTM; E2F1-/- mouse, and carcinomas arising in the skin of RbF/F;K14creERTM; E2F1-/- mouse. All mice were treated with tamoxifen.

2012-08-20 | E-GEOD-38048 | biostudies-arrayexpress

E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis

2012-08-20 | GSE38048 | GEO

Identification of the RB loss-induced transcriptome in prostate cancer [RNA]

Project description:The retinoblastoma protein (RB) is preferentially lost in the progression to castrate resistant prostate cancer (CRPC). However, the alterations associated with such loss have been scantly described. The current study aims to provide molecular mechanisms underlying Rb loss-driven CRPC phenotypes

2018-02-19 | GSE94863 | GEO

Comparison of the RB loss-induced transcrptiome in hormone-therapy sensitive and castration-resistant prostate cancer [RNA-seq]

Project description:These studies examine the biological networks altered after RB loss across prostate cancer progression.

2021-04-26 | GSE154190 | GEO

RB1 loss promotes a noncanonical activator function of LSD1 and sensitizes castration-resistant prostate cancer to LSD1 inhibition [ChIP-seq]

Project description:Genomic loss of RB1 is a common alteration in castration-resistant prostate cancer (CRPC) and is associated with poor patient outcomes. RB1-loss is also a driver event that promotes the neuroendocrine transdifferentiation of prostate cancer (PCa). The loss of Rb protein disrupts the Rb-E2F repressor complex and thus hyperactivates E2F transcription activators. While the impact of RB1-loss on PCa progression and linage plasticity has been previously studied, the underline mechanisms remain unclear. Using an integrated cistromic and transcriptomic analysis, we have characterized Rb activities in multiple CRPC models by identifying Rb directly regulated genes and revealed that Rb has distinct binding sites and targets in TP53-mutated CRPC. Significantly, we show that RB1-loss promotes the noncanonical activator function of LSD1/KDM1A, which stabilizes chromatin binding of E2F1, and hence sensitizes CRPC tumor to the LSD1 inhibitor treatment. These results provide new molecular insights of Rb activity in PCa progression and suggest LSD1 as a potential therapeutic target in CRPC with RB1-loss.

2022-01-14 | GSE176402 | GEO

RB1 loss promotes a noncanonical activator function of LSD1 and sensitizes castration-resistant prostate cancer to LSD1 inhibition [RNA-seq]

2022-01-14 | GSE176403 | GEO